Search research articles
Contact Us
Filters
Showing results (31-40 of 41) with videos related to
Page
of 5
Sort By:
JCO Precision Oncology
|
May 10, 2023
The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State
Jens Rueter, Eric C Anderson, Leah C Graham, et al.
NPJ Precision Oncology
|
March 9, 2024
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI)
Eric C Anderson, John DiPalazzo, F Lee Lucas, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Cell Reports. Medicine
|
May 3, 2023
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial
Tulika Ranjan, Soma Sengupta, Michael J Glantz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2016
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper, Lars Riedemann, Zohreh Amoozgar, et al.
Nature Cancer
|
October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Isao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer
|
September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Isao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data
Tulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 41) with videos related to
Sort By:
Page
of 5
JCO Precision Oncology
|
May 10, 2023
The Maine Cancer Genomics Initiative: Implementing a Community Cancer Genomics Program Across an Entire Rural State
Jens Rueter, Eric C Anderson, Leah C Graham, et al.
NPJ Precision Oncology
|
March 9, 2024
Genome-matched treatments and patient outcomes in the Maine Cancer Genomics Initiative (MCGI)
Eric C Anderson, John DiPalazzo, F Lee Lucas, et al.
Neuro-Oncology
|
July 6, 2013
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
Christine Lu-Emerson, Matija Snuderl, Nathaniel D Kirkpatrick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by <i>ROS1</i> Fusions
Hiroki Sato, Adam J Schoenfeld, Evan Siau, et al.
Cell Reports. Medicine
|
May 3, 2023
Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial
Tulika Ranjan, Soma Sengupta, Michael J Glantz, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 6, 2013
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T Batchelor, Elizabeth R Gerstner, Kyrre E Emblem, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 5, 2016
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper, Lars Riedemann, Zohreh Amoozgar, et al.
Nature Cancer
|
October 9, 2023
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Isao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Nature Cancer
|
September 24, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Isao Miyazaki, Igor Odintsov, Keiji Ishida, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data
Tulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Page
of 5